13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001822947
Total reported value
$113.1M
$113.1M
30 檔
35.8%
According to the latest 13F quarterly dataset, Ally Bridge Group managed an equity portfolio of $113.1M at the end of Q4 2024, spanning 30 distinct U.S. exchange-listed positions.
In Q4 2024, Ally Bridge Group adopted a defensive or profit-taking posture, trimming 19 positions and completely liquidating 8 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 10.58% | — | — | |
| 2 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 8.22% | -4.58% | EXIT | |
| 3 | INSM | Insmed Inc | Stock-Healthcare | 6.77% | — | -24.18% | |
| 4 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 4.84% | +3.57% | NEW | |
| 5 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 4.35% | — | -38.95% | |
| 6 | CGON | Cg Oncology Inc | Stock-Other | 4.28% | — | -33.89% | |
| 7 | ✓ | Merus N V | Stock-Other | 4.21% | — | -43.91% | |
| 8 | 2655787D | Blueprint Medicines CORP | Stock-Other | 4.18% | — | -47.31% | |
| 9 | JANX | Janux Therapeutics Inc | Stock-Other | 4.14% | — | -17.02% | |
| 10 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 3.51% | — | -21.02% | |
| 11 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 3.38% | -10.82% | EXIT | |
| 12 | GERN | Geron CORP | Stock-Other | 3.26% | — | -19.25% | |
| 13 | ALMS | Alumis Inc | Stock-Other | 3.00% | -1.07% | +6.42% | |
| 14 | PRAX | Praxis Precision Medicines I | Stock-Other | 2.97% | -8.54% | EXIT | |
| 15 | TRVI | Trevi Therapeutics Inc | Stock-Other | 2.76% | — | -40.92% | |
| 16 | ELVN | Enliven Therapeutics Inc | Stock-Other | 2.73% | — | -39.66% | |
| 17 | KRRO | Korro Bio Inc | Stock-Other | 2.31% | — | — | |
| 18 | JSPR | Jasper Therapeutics Inc | Stock-Other | 2.24% | — | -69.35% | |
| 19 | EYPT | Eyepoint Inc | Stock-Other | 2.22% | — | — | |
| 20 | WHWK | Whitehawk Therapeutics Inc | Stock-Other | 2.21% | +1.03% | — | |
| 21 | ATYR | Atyr Pharma Inc | Stock-Other | 2.17% | — | — | |
| 22 | ETNBGBP | 89bio Inc | Stock-Other | 2.13% | — | — | |
| 23 | TYRA | Tyra Biosciences Inc | Stock-Other | 2.09% | — | -35.18% | |
| 24 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 1.99% | — | — | |
| 25 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 1.97% | — | -58.11% | |
| 26 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 1.90% | -1.11% | -55.69% | |
| 27 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 1.69% | — | -75.98% | |
| 28 | CNTX | Context Therapeutics Inc | Stock-Other | 1.42% | — | -10.29% | |
| 29 | PMNEUR | Promis Neurosciences Inc | Stock-Other | 1.29% | — | — | |
| 30 | CLYM | Climb Bio Inc | Stock-Other | 1.17% | +2.87% | NEW |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ITCIEUR | Intra-cellular Therapies Inc | +10.6% | NEW | New buy |
| 2 | AXSM | Axsome Therapeutics Inc | +4.8% | NEW | New buy |
| 3 | SLNOEUR | Soleno Therapeutics Inc | +3.4% | NEW | New buy |
| 4 | TARS | Tarsus Pharmaceuticals Inc | +2.6% | -46.21% | Trim |
| 5 | KRRO | Korro Bio Inc | +2.3% | NEW | New buy |
| 6 | EYPT | Eyepoint Inc | +2.2% | NEW | New buy |
| 7 | WHWK | Whitehawk Therapeutics Inc | +2.2% | NEW | New buy |
| 8 | ATYR | Atyr Pharma Inc | +2.2% | NEW | New buy |
| 9 | ETNBGBP | 89bio Inc | +2.1% | NEW | New buy |
| 10 | DNTH | Dianthus Therapeutics Inc | +2% | NEW | New buy |
| 11 | JANX | Janux Therapeutics Inc | +1.5% | -17.02% | Trim |
| 12 | INSM | Insmed Inc | +0.9% | -24.18% | Trim |
| 13 | 260 | Centessa Pharmaceuticals-adr | +0.9% | -21.02% | Trim |
| 14 | PRAX | Praxis Precision Medicines I | +0.7% | -38.54% | Trim |
| 15 | ALMS | Alumis Inc | +0.6% | +6.42% | Add |
| 16 | TRVI | Trevi Therapeutics Inc | +0.4% | -40.92% | Trim |
| 17 | PMNEUR | Promis Neurosciences Inc | +0.2% | — | Unchanged |
| 18 | GERN | Geron CORP | 0% | -19.25% | Trim |
| 19 | XENE | Xenon Pharmaceuticals Inc | -0.1% | -38.95% | Trim |
| 20 | CNTX | Context Therapeutics Inc | -0.4% | -10.29% | Trim |
| 21 | BRD1EUR | Mind Medicine Mindmed Inc | -0.4% | -58.11% | Trim |
| 22 | ELVN | Enliven Therapeutics Inc | -0.5% | -39.66% | Trim |
| 23 | EWTX | Edgewise Therapeutics Inc | -0.8% | -55.69% | Trim |
| 24 | CGON | Cg Oncology Inc | -1% | -33.89% | Trim |
| 25 | 2655787D | Blueprint Medicines CORP | -1.1% | -47.31% | Trim |
| 26 | TYRA | Tyra Biosciences Inc | -1.3% | -35.18% | Trim |
| 27 | ✓ | Merus N V | -1.4% | -43.91% | Trim |
| 28 | JSPR | Jasper Therapeutics Inc | -1.8% | -69.35% | Trim |
| 29 | CLYM | Climb Bio Inc | -2.2% | -38.16% | Trim |
| 30 | SWTXUSD | Springworks Therapeutics Inc | -2.2% | -75.98% | Trim |
| 31 | RLAY | Relay Therapeutics Inc | -2.4% | EXIT | Sold out |
| 32 | CATX | Perspective Therapeutics Inc | -2.4% | EXIT | Sold out |
| 33 | IRON | Disc Medicine Inc | -2.6% | EXIT | Sold out |
| 34 | APLT | Applied Therapeutics Inc | -2.8% | EXIT | Sold out |
| 35 | KURA | Kura Oncology Inc | -3.1% | EXIT | Sold out |
| 36 | RVMD | Revolution Medicines Inc | -4% | EXIT | Sold out |
| 37 | ✓ | Longboard Pharmaceuticals In | -4.3% | EXIT | Sold out |
| 38 | SRPT | Sarepta Therapeutics Inc | -4.8% | EXIT | Sold out |
According to official SEC Form 13F filings, Ally Bridge Group reported a total U.S. public equity portfolio value of $113.1M across 30 disclosed positions in Q4 2024.
During Q4 2024, Ally Bridge Group's top holdings by market value included ITCIEUR (10.6%)、TARS (8.2%)、INSM (6.8%). The largest single position, ITCIEUR, represented 10.6% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ITCIEUR, TARS, INSM) accounted for 35.8% of total reported equity market value during Q4 2024.
Top New Position Initiated
ITCIEUR
市值: $12.3M
Top Position Liquidated / Trimmed
SRPT
前期市值: $9.0M
In Q4 2024, Ally Bridge Group made 37 total portfolio adjustments, initiating 9 new buys, adding to 1 positions, trimming 19 holdings, and fully liquidating 8 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.